CLINICAL TRIALS PROFILE FOR FORMOTEROL FUMARATE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for FORMOTEROL FUMARATE
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Combination | NCT03906045 ↗ | A Scintigraphy Study of PT010 in COPD Patients | Completed | Simbec Research | Phase 1 | 2019-04-04 | This study is a single treatment period, single dose gamma scintigraphy study investigating the deposition in the lungs of a Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF-MDI). This study will be investigating how the drug (known as PT010) is distributed in the lungs of Chronic Obstructive Pulmonary Disease (COPD) patients (with moderate to very severe COPD) following a maximal 10 second breath hold. This inhaler is intended to be used in the treatment of COPD, which is a group of diseases which cause lung problems and difficulty breathing. PT010 is a new combination product of 3 marketed drugs called Glycopyrronium, Formoterol Fumarate and Budesonide. |
| New Combination | NCT03906045 ↗ | A Scintigraphy Study of PT010 in COPD Patients | Completed | AstraZeneca | Phase 1 | 2019-04-04 | This study is a single treatment period, single dose gamma scintigraphy study investigating the deposition in the lungs of a Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF-MDI). This study will be investigating how the drug (known as PT010) is distributed in the lungs of Chronic Obstructive Pulmonary Disease (COPD) patients (with moderate to very severe COPD) following a maximal 10 second breath hold. This inhaler is intended to be used in the treatment of COPD, which is a group of diseases which cause lung problems and difficulty breathing. PT010 is a new combination product of 3 marketed drugs called Glycopyrronium, Formoterol Fumarate and Budesonide. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for FORMOTEROL FUMARATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00139932 ↗ | Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272) | Completed | Integrated Therapeutics Group | Phase 4 | 2005-09-01 | This study is being conducted to determine if the co-administration of formoterol fumarate and tiotropium bromide is more effective than the use of tiotropium bromide alone in patients with COPD. |
| NCT00139932 ↗ | Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272) | Completed | Novartis | Phase 4 | 2005-09-01 | This study is being conducted to determine if the co-administration of formoterol fumarate and tiotropium bromide is more effective than the use of tiotropium bromide alone in patients with COPD. |
| NCT00139932 ↗ | Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2005-09-01 | This study is being conducted to determine if the co-administration of formoterol fumarate and tiotropium bromide is more effective than the use of tiotropium bromide alone in patients with COPD. |
| NCT00215358 ↗ | Study in Patients With Asthma | Completed | Dey | Phase 2 | 2002-07-01 | The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control drug. |
| NCT00215371 ↗ | Study in Patients With Asthma | Completed | Dey | Phase 2 | 2002-07-01 | The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control group. |
| NCT00215384 ↗ | Study in Patients With COPD | Completed | Dey | Phase 2 | 1969-12-31 | The purpose of this study is to determine which dose of the investigational drug is the most safe and effective compared to the control drug. |
| NCT00215397 ↗ | Study in Patients With Asthma | Completed | Dey | Phase 2 | 1969-12-31 | The purpose of this study is to determine which dose of the investigational drug is the most safe and effective in the treatment of asthma compared to the control drug. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FORMOTEROL FUMARATE
Condition Name
Clinical Trial Locations for FORMOTEROL FUMARATE
Trials by Country
Clinical Trial Progress for FORMOTEROL FUMARATE
Clinical Trial Phase
Clinical Trial Sponsors for FORMOTEROL FUMARATE
Sponsor Name
